For patients with major depression, there was a clinically meaningful but not statistically significant improvement in the primary endpoint with 20-mg azetukalner. There were significant improvements ...

Investigational seltorexant improved symptoms of major depressive disorder (MDD) and insomnia in people with an inadequate response to antidepressants, a phase III trial indicated. By week 6, the ...

On the heels of positive phase II results of its extended-release ketamine (R-107) in treatment-resistant depression, Douglas Pharmaceuticals Ltd. is gearing up to begin phase III trials of its ...

Hitting the primary endpoint on Compass Pathways plc’s Comp005 study of synthetic psilocybin, which the company billed as the first classic psychedelic to report phase III efficacy data, produced only ...